

08 115073

Patent Application  
A-0104




Figure 1

Figure 2A, 2B

Patent Application  
A-0104

A

B





Figure 3

08 115073

Patent Application  
A-0104





Figure 4



TAb 252

NIH3T3-c-erbB-2 lysate + S<sup>35</sup> labeled cl.4-3 supernatant

00769509:012501  
T092T0:80569260

Figure 5

Radioimmunoprecipitation of gp75 from SKBR3 Supernatant





Figure 6

Radioimmunoprecipitation of Supernatants From Various Cell Lines



Comparison of Standards in Sandwich IRMA




Figure 7

Analysis of Nude Mouse Sera  
In c-erbB-2 IRMA





Figure 8



Analysis of Nude Mouse Sera in the c-erbB-2 IRMA  
 Treated vs. Untreated



103210-60569260

# Analysis of Normal Human Sera in the c-erbB-2 IRMA





Figure 10

103210-80569/60

# Analysis of 20 Sera from Human Breast Cancer Patients Serial Samples Assayed in the Sandwich IRMA



08 115073  
Patent Application  
A-0104

Figure 11

Sandwich IRMA: Human Breast Sera and Control Sera




Figure 12

105210-80569260

C-erbB-2 Competition ELISA  
Tab 251 Binding to NIH3T3t Lysate




Figure 13

FO5210-30565/60

C-erbB-2 Competition ELISA  
TAB 251 Binding to NIH3T3t Lysate




Figure 14

C-erbB-2 Competition ELISA  
 TAB 251 Binding to NIH3T3t Lysate




Figure 15

[illegible]

Figure 16